Eurofins Scientific (ENXTPA:ERF) has stepped up its capital return activity, reporting the repurchase of 150,000 shares during the week of 12 to 16 October 2026 under its ongoing buyback programme.
The buyback comes against a backdrop of firm price momentum for Eurofins Scientific, with a 30-day share price return of 3.35% building on an 11.93% 90-day gain and a 27.42% year to date rise. The 1-year total shareholder return sits at 27.90%, and the 3-year total shareholder return reaches 74.87%, despite a 5-year total shareholder return that is down 17.80%.
Look beyond Eurofins Scientific and compare how other lab testing and healthcare players stack up on quality and value using our curated 192 high quality undervalued stocks.
Bulls point to Eurofins Scientific’s recent buyback and solid shareholder returns. Bears flag the weaker 5-year record and valuation concerns. Which side do today’s numbers lean toward as you weigh what the shares are worth?
Most Popular Narrative: 9% Overvalued
On the narrative view, Eurofins Scientific’s fair value of €72.29 sits below the last close at €79.00. This frames the buyback against a richer starting point and puts more weight on execution than on re rating.
Growing free cash flow, evidenced by a fivefold increase over three years and €403m generated in the first half of 2026 with 47% cash conversion, provides Eurofins Scientific with more capacity for debt control and share buy backs, which can support earnings per share and underpin the current valuation.
See why 21 investors see Eurofins Scientific as 9% overvalued.
Result: Fair Value of €72.29 (OVERVALUED)
Still, if Eurofins Scientific’s BioPharma weakness lingers or North American diagnostics face further reimbursement pressure, the cash flow story behind that 9% premium could crack.
Find out about the key risks to this Eurofins Scientific narrative.
Another View: What Eurofins Scientific’s P/E Is Really Saying
A second lens tells a different story. Eurofins Scientific trades on a P/E of 29.2x, below the Global Life Sciences average at 37.5x and under the peer group on 33.4x. Yet it still sits a touch above the fair ratio of 28.4x, which points to limited margin for error if sentiment cools.
To see how that price tag lines up with the underlying numbers and where valuation pressure could build or ease, See what the numbers say about this price — find out in our valuation breakdown.
For a clearer view of how Eurofins Scientific’s earnings multiple stacks up against the wider sector right now,
Next Steps
Mixed messages on Eurofins Scientific’s valuation and momentum can create noise. Move quickly, review the numbers for yourself, and weigh the 3 key rewards and 1 important warning sign
Looking for more Eurofins Scientific style investment ideas?
If Eurofins Scientific has sharpened your focus on valuation and quality, do not stop here. The next opportunity on your list could be only one screening away.
- Target stronger income potential by reviewing companies that currently appear in our 222 dividend fortresses.
- Reduce portfolio gut checks and focus on durability with the help of our 229 resilient stocks with low risk scores.
- Spot tomorrow's potential standouts before they gain wider attention by scanning the 615 high quality undiscovered gems.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com